<DOC>
<DOCNO>
EP-0007690
</DOCNO>
<TEXT>
<DATE>
19800206
</DATE>
<IPC-CLASSIFICATIONS>
C12P-19/04 <main>C12P-19/04</main> C12P-19/00 
</IPC-CLASSIFICATIONS>
<TITLE>
process for the production of a polysaccharide.
</TITLE>
<APPLICANT>
talres devnl <sep>tate & lyle patent holdingsbm <sep>talres development (n.a.) n.v. <sep>tate & lyle patent holdings limited<sep>talres development (n.a.) n.v.breedestraat 39ccuraçao, netherlands antillesnl<sep>tate &amp; lyle patent holdings limited5th floor, triningham building front streethamilton 5bm<sep>talres development (n.a.) n.v.<sep>tate & lyle patent holdings limited<sep>
</APPLICANT>
<INVENTOR>
govan john richard watson<sep>jarman trevor rodney<sep>govan, john richard watson<sep>jarman, trevor rodney<sep>govan, john richard watson25c, market streetmusselburgh edinburghgb<sep>jarman, trevor rodney45, loxwood earleyreading berkshiregb<sep>govan, john richard watson<sep>jarman, trevor rodney  <sep>govan, john richard watson 25c, market streetmusselburgh edinburghgb<sep>jarman, trevor rodney45, loxwood earleyreading berkshiregb<sep>
</INVENTOR>
<ABSTRACT>
a process for the production of polysaccharide consisting  of a partially acerylated variable block copolymer of  d-mannuronic and l-guluronic acid residues, comprises  cultivating in a nutrient medium therefor a strain of pseudo­ monas, which is non-pathogenic to humans, and which has  been obtained by treating a non-mucoid species of pseudo­ monas, which is non-pathogenic to humans, with a b-lactam  or aminoglycoside antibiotic whereby a mucoid strain tole­ rant to said antibiotic was selected, and isolating from the  medium the polysaccharide produced.  
</ABSTRACT>
</TEXT>
</DOC>
